^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ilorasertib (ABT348)

    i
    Other names: ABT348, Abbott-968660, A-968660.0, ABT-348, ABT 348
    Associations
    News

    Trials

    Company:
    AbbVie
    Drug class:
    VEGFR inhibitor, PDGFR inhibitor, Aurora kinase inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery (NCT02540876)
    Phase 1
    University of Chicago
    Completed
    Last update posted :
    04/22/2019
    Initiation :
    09/08/2015
    Primary completion :
    02/08/2019
    Completion :
    02/08/2019
    CDKN2A
    |
    CDKN2A deletion • CDKN2A mutation
    |
    ilorasertib (ABT348)